| Methods |
Randomized
Double‐blind
Parallel‐group
Placebo‐controlled
Duration: 24 weeks |
| Participants |
Country: United States
No. of Centers: 1
Diagnosis: Probable Alzheimer's disease
Diagnosis defined by: DSM‐III (Diagnostic and Statistical Manual of Mental Disorders‐ Third Edition),
NINCDS‐ADRDA (National Institute of Neurological and Communicative Disorders and Strokes, and the Alzheimer's Disease and Related Disorders Association).
Inclusion: Modified Hachinski Ischemic Scoring Scale < 4.
Mini Mental State Examination: range (10‐23)
Hamilton Psychiatric Rating Scale for Depression <19
Inventory of Psychic and Somatic complaints in the Elderly
Exclusions: evidence of multi‐infact on CT, MRI, labs, or physical exam
Total No. of patients: 80
Sex: 46 women, 34 men
Age: Hydergine mean was 72, Placebo mean was 70, range (55‐79) |
| Interventions |
Route: oral
Treatment: Hydergine‐LC 1mg t.i.d.
Control: Placebo t.i.d. |
| Outcomes |
WAIS (Wechsler Adult Intelligence Scale), Digit Symbol Substitution Test, Russell revision of the Wechsler Memory Scale (Logical Memory and Visual Reproduction), IPSC‐E (Inventory of Psychic and Somatic Complaints in the Elderly), SCAG (Sandoz Clinical Assessment Geriatric Scale), GERRI (Geriatric Evaluation by Relatives Rating Instrument), HDRS (Hamilton Psychiatric Rating Scale for Depression) |
| Notes |
No. excluded after randomization: not stated
No. not included in analysis: Total=12, Treatment=6, Control=6. |
